TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03607539
Drug: Platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.
Study: NCT01916200
Drug: Paroxetine CR
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
Study: NCT00054184
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00054184
Drug: paclitaxel poliglumex
Normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04027361
Drug: Amphetamine Extended Release (ER) Tablet 20 mg
Normalized name: amphetamine Extended Release Oral Tablet
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 20 mg dose of amphetamine ER Tablet, orally administered
Study: NCT01992042
Drug: Pimonidazole
Normalized name: Pimonidazole
DrugBank: Pimonidazole (DB12485)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00679237
Drug: statins, ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cholesterol reduction according to ESC guidelines
Study: NCT00679237
Drug: metformin, glimepiride, insulin
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: s.glucose control according to ESC guidelines
Study: NCT00923533
Drug: Fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
Study: NCT00923533
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
Study: NCT00099918
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02675205
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel: efficacy and safety in cerebral aneurysm stenting
Study: NCT02424344
Drug: Aclidinium/Formoterol
Normalized name: ACLIDINIUM/FORMOTEROL
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
Study: NCT03128203
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin, intranasally administrated
Study: NCT04252937
Drug: Adrecizumab
Normalized name: Adrecizumab
DrugBank: Enibarcimab (DB16730)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).
Study: NCT02675205
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor:efficacy and safety in cerebral aneurysm stenting
Study: NCT02675205
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03685747
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin one-time 20 mg/kg intraperitoneal dose.
Study: NCT01769235
Drug: Vehicle of test product
Normalized name: Dental Resources brand of Stannous Fluoride Dental Product
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
Study: NCT03311555
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240mg tablet daily for 36 weeks
Study: NCT03082300
Drug: naquotinib
Normalized name: Naquotinib
DrugBank: Naquotinib (DB12036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02123966
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03311555
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
Study: NCT00505635
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m\^2 By Mouth Every 4 Hours x 3 Doses On Day 1
Study: NCT00505635
Drug: Velban
Normalized name: Velban
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/m\^2 By Vein Over 15-30 Minutes On Days 1-4
Study: NCT00505635
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m\^2 By Vein Over 45-120 Minutes On Days 1-4
Study: NCT00505635
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 MIU/m\^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
Study: NCT00505635
Drug: Intron-A
Normalized name: Intron-A
DrugBank: Interferon alfa-2c (DB15131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mu/m\^2 Subcutaneously (Under the skin) Daily On Days 1-5
Study: NCT00505635
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg By Mouth Daily
Study: NCT02981940
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib capsule
Study: NCT01536262
Drug: Tiotropium + Olodaterol
Normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium and Olodaterol FDC once daily inhalation
Study: NCT01536262
Drug: Olodaterol
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol once daily inhalation
Study: NCT01200420
Drug: miravirsen
Normalized name: Miravirsen
DrugBank: Miravirsen (DB12851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT00730418
Drug: Doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with doxazosin 4mg daily for 24 mos
Study: NCT00730418
Drug: Doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with doxazosin 8mg daily for 24 mos
Study: NCT01445639
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
Study: NCT04370093
Drug: Pioglitazone 45 mg
Normalized name: pioglitazone 45 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
Study: NCT06036030
Drug: Dihydroartemisinin
Normalized name: Dihydroartemisinin
DrugBank: Artenimol (DB11638)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
Study: NCT06036030
Drug: Piperaquine
Normalized name: Piperaquine
DrugBank: Piperaquine (DB13941)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
Study: NCT06036030
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
Study: NCT00839228
Drug: Perhexiline
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg o bd for 3 months
Study: NCT01200420
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC injection
Study: NCT02262143
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 160mg, qd, po
Study: NCT02146651
Drug: BioChaperone insulin lispro 0.2U/Kg
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 0.2U/Kg body weight injected subcutaneously
Study: NCT02146651
Drug: BioChaperone insulin lispro 0.1U/Kg
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 0.1U/Kg body weight injected subcutaneously
Study: NCT02146651
Drug: BioChaperone insulin lispro 0.4U/Kg
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 0.4U/Kg body weight injected subcutaneously
Study: NCT00001457
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000568
Drug: ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00702351
Drug: Org 36286 (corifollitropin alfa)
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing \>= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing \<= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
Study: NCT02442414
Drug: KBP-5209
Normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
Study: NCT04533568
Drug: Dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
Study: NCT02451930
Drug: Necitumumab
Normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02451930
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT03639675
Drug: Aflibercept (EYLEA, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg (0.05 mL), Intravitreal injection (IVT), single dose.
Study: NCT03639675
Drug: Topical IOP-lowering drugs
Normalized name: Avena sativa flowering top
DrugBank: Avena sativa flowering top (DB14253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
Study: NCT02160626
Drug: A-101 Vehicle
Normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection [Penmenvy]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT00717067
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 300 mg (150 mg x 2 tablets) x single dose
Study: NCT00717067
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 150 mg tablet twice daily x 7 days
Study: NCT00717067
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir 100 mg capsule twice daily x 7 days
Study: NCT00717067
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
Study: NCT00717067
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 150 mg tablet once daily x 7 days
Study: NCT00717067
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 150 mg tablet once every 48 hours x 7 days
Study: NCT02580682
Drug: Sanfu herbal patch
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
Study: NCT00717067
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
Study: NCT04324229
Drug: Liraglutide 6 MG/ML [Victoza]
Normalized name: liraglutide 6 MG/ML [Victoza]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.
Study: NCT02580682
Drug: Sanfu moxibustion
Normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
DrugBank: Butylene glycol (DB14110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
Study: NCT00717067
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
Study: NCT02090959
Drug: Ataluren
Normalized name: Ataluren
DrugBank: Ataluren (DB05016)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Ataluren will be administered per the dose and schedule specified in the arm.
Study: NCT02580682
Drug: Sanfu herbal patch and moxibustion
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: use Sanfu moxibustion followed by Sanfu herbal patch
Study: NCT03623711
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
Study: NCT03899987
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03899987
Drug: Rintatolimod
Normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03623711
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.
Study: NCT03623711
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.
Study: NCT04502667
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000U or 2000U every 24 hours orally
Study: NCT01746173
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01746173
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01746173
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01746173
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01746173
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01746173
Drug: Palifermin
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01746173
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01746173
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01746173
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04552808
Drug: Yimitasvir Phosphate
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
Study: NCT01689337
Drug: Sprifermin (AS902330)
Normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Study: NCT01689337
Drug: Sprifermin (AS902330)
Normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Study: NCT02431013
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.
Study: NCT04552808
Drug: Yimitasvir Phosphate
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
Study: NCT00997334
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00560963
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03913234
Drug: Ribociclib, Trastuzumab, Letrozole
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
Study: NCT01182025
Drug: Xiyanping Injection with western medicine
Normalized name: western ragweed pollen extract Injectable Suspension
DrugBank: Ragweed pollen extract (DB05368)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Symptomatic treatment using the same treatment methods in Xiyanpin injection group.
Study: NCT00641056
Drug: Exenatide Once Weekly
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection, 2.0mcg, once weekly
Study: NCT00641056
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous injection, variable dose, QD
Study: NCT01923558
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil Hydrochloride tablets,23 mg
Study: NCT01627132
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg QD
Study: NCT00822172
Drug: cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.
Study: NCT02584582
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02584582
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02818816
Drug: brimonidine tartrate 0.2%
Normalized name: BRIMONIDINE TARTRATE 0.2% SOLN,OPH
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alpha adrenergic receptor agonist
Study: NCT01703351
Drug: 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)